The growth in disease registries

Posted June 29th, 2012

The current policy environment has broadened the scope of evidence that life sciences companies must provide to health care stakeholders. In the United States, the focus is on comparative effectiveness research (CER), and in many other parts of the world, relative effectiveness/efficacy.

View the full article